Liver failure
Drug research and approvals for liver failure: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 121 studies of liver failure are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 14 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 121
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- A Single-Center, Prospective Clinical Cohort Study on Perioperative Management, Exposure, Multiorgan Outcomes, and…NCT07946146 · Not reported · Beijing Tsinghua Chang Gung Hospital · starts Oct 22, 2026
- A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentNCT07853040 · Phase 1 · Incyte Corporation · starts Oct 27, 2026
- Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · Not applicable · Air Force Military Medical University, China · starts Sep 1, 2026
- Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary AtresiaNCT07797673 · Phase 1 · Dr Cipto Mangunkusumo General Hospital · starts Sep 1, 2026
- Liver and Coagulation Disorders in Cardiac Transthyretin AmyloidosisNCT07766135 · Not reported · University of Messina · starts Jan 30, 2026
- Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver FailureNCT07765823 · Not applicable · King Edward Medical University · starts Jul 16, 2026
- CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver FailureNCT07727759 · Not reported · Minia University · starts Aug 15, 2026
- DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable…NCT07717437 · Not reported · Maastricht University Medical Center · starts Mar 16, 2021
- Restrictive Fluid Management In Liver Transplantation (REFIL)NCT07695363 · Not applicable · Centre hospitalier de l'Université de Montréal (CHUM) · starts Feb 15, 2026
Approved 1
- TolcaponeCatechol O-methyltransferase inhibitor
Phase 3 3
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PentoxifyllineAdenosine A2 receptor antagonist
- SomatostatinSomatostatin receptor agonist
Phase 2 4
- TacrolimusFK506-binding protein 1A inhibitor
- EntecavirDNA polymerase/reverse transcriptase inhibitor
- TerlipressinVasopressin V1 receptor binding agent
- Silibinin
Phase 1 or earlier 3
- IcenticaftorCystic fibrosis transmembrane conductance regulator activator
- LofexidineAdrenergic receptor alpha-2 agonist
- Latrepirdine
How its trials ended
450 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 77 whose ending is known, 35% met their primary endpoint, 3% missed it and 62% stopped early.
- Completed, result not reported18641%
- Status unknown10122%
- Ongoing8619%
- Stopped: other or unclear307%
- Met its primary endpoint276%
- Stopped: sponsor or business decision61%
- Stopped: enrollment or feasibility51%
- Stopped: lack of efficacy31%
- Stopped: funding31%
- Missed its primary endpoint2<1%
- Stopped: safety1<1%
| Aug 10, 2026 | Selective inhibitor of dual-specific protein kinase…Prevention of post-hepatectomy liver failure | HepaRegeniX GmbH | Designated |
| Mar 6, 2026 | NitazoxanideTreatment of acute-on-chronic liver failure | Genfit | Designated |
| Jan 25, 2024 | Signal regulatory protein alpha (SIRPalpha)-ExosomeTreatment of acute liver failure regardless of etiology | Shiftbio Inc. | Designated |
| Sep 9, 2020 | Bioartificial liver system utilizing encapsulated human Hep…Treatment of Acute Liver failure. | ESPL Regulatory Consulting Limited | Designated |
| Jun 16, 2020 | GeranylgeranylacetonePrevention of post-hepatectomy liver failure | RNR BioMedical Inc. | Designated |
| Mar 15, 2018 | TrimetazidineTreatment of acute-on-chronic liver failure | Martin Pharmaceuticals, Inc. | Designated |
| Jun 21, 2017 | Citric acid monohydrateTreatment of acute-on-chronic liver failure | Genfit SA | Designated |
| Sep 13, 2011 | Cardiotrophin-1Treatment of acute liver failure | Digna Biotech, S.L. | Designated |
| May 11, 2011 | Human Hepatocarcinoma-Intestine-pancreas/pancreatitis…Treatment of acute liver failure | Vivo Bioscience Company Limited | Designated |
| Apr 7, 2010 | L-ornithine phenylacetateTreatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase | Amalive Limited | Designated |
| Jul 16, 2004 | Immortalized human liver cells found in the extracorporeal…Treatment of fulminant hepatic failure (acute liver failure) | Vital Therapies, Inc. | Designated |
| Sep 9, 2002 | N-acetylcysteineTreatment of acute liver failure | Cumberland Pharmaceuticals, Inc. | Designated |
| Feb 11, 2002 | Bioartificial liver system utilizing xenogenic hepatocytes…Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2 | Excorp Medical, Inc. | Designated |
| Nov 27, 1998 | Xenogeneic hepatocytesTreatment of severe liver failure. | Circe Biomedical, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 30, 2009 | ZutectraHuman hepatitis B immunoglobulin | Biotest Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA